Pharvaris (NASDAQ:PHVS) Hits New 1-Year High – Here’s Why

Pharvaris N.V. (NASDAQ:PHVS)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $33.50 and last traded at $33.3850, with a volume of 81367 shares changing hands. The stock had previously closed at $31.46.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PHVS shares. Royal Bank Of Canada lowered their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research report on Tuesday. Finally, Wedbush lifted their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $49.18.

Pharvaris Trading Up 5.5%

The business’s fifty day simple moving average is $29.71 and its 200-day simple moving average is $27.63. The firm has a market cap of $2.17 billion, a P/E ratio of -10.40 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Analysts anticipate that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Insider Activity

In other news, Director Viviane Monges sold 9,667 shares of Pharvaris stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.29, for a total transaction of $292,813.43. Following the sale, the director owned 5,500 shares of the company’s stock, valued at approximately $166,595. The trade was a 63.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David W. Nassif sold 10,000 shares of Pharvaris stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.31, for a total transaction of $303,100.00. Following the sale, the chief financial officer directly owned 120,300 shares in the company, valued at $3,646,293. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 212,618 shares of company stock worth $6,350,564.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently bought and sold shares of PHVS. Wellington Management Group LLP bought a new stake in Pharvaris during the third quarter worth about $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Pharvaris during the third quarter worth about $15,613,000. Commodore Capital LP boosted its stake in Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. boosted its stake in Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after acquiring an additional 500,000 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.